About WordPress

Search

↓ Skip to Main Content

the new generation glocalized network in theragenomic and personalized medicine and the genetics of patient's individualized drug safety

search: thasso

Search for:

Log in

Main Navigation

english
- english
- français
- deutsch
- italiano
- español
- português
thasso
thasso: post
thasso: community
thasso: resources
thasso: academy
thasso: about
donations $
Cookie Policy (EU)

Home › Posts tagged Autoimmune Disorder

Tag: Autoimmune Disorder

First ever treatment for Lambert-Eaton myasthenic syndrome (LEMS) FDA approved

By Joseph Gut - thasso Posted on December 4, 2018 Posted in New Drug Approval, Rare Diseases, Regulatory Announcement, Thasso Post, Theragenomic Medicine No Comments Tagged with American Food & Drug Administration (FDA), Amifampridine (Firdapse), Autoimmune Disorder, Lambert-Eaton Myasthenic Syndrome (LEMS), Rare Disease, Thasso Post, Theragenomic Medicine

First ever treatment for Lambert-Eaton myasthenic syndrome (LEMS) FDA approved

December 04, 2018 – The American Food and Drug Administration (FDA) has just approved its first ever treatment, Amifampridine (Firdapse), for Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder for adult patients. LEMS affects the connection between nerves and muscles …

First ever treatment for Lambert-Eaton myasthenic syndrome (LEMS) FDA approved Read more »

FDA: Potential Signals of Serious Risks/New Safety Information Identified from the Adverse Event Reporting System (AERS) between January – March 2009

By Joseph Gut - thasso Posted on October 9, 2009 Posted in Adverse Drug Reaction [ADR] No Comments Tagged with Anaphylaxis, Autoimmune Disorder, Colitis, Gangrene, Gastrointestina Perforation, Hemolytic Anemia, Hypersensitivity Reaction, Liver Damage, Portal Hypertension, Pulmonary Hypertension, Renal Impairment, Safety in Pregnancy

October 9, 2009 – The American Food and Drug Administration (FDA) has just published the list below with the names of drug products and potential signals of serious risks/new safety information that were identified for these products during the period …

FDA: Potential Signals of Serious Risks/New Safety Information Identified from the Adverse Event Reporting System (AERS) between January – March 2009 Read more »

Optional: Social Subscribe/Login

thasso: donate

We need your help. Please support the development of thasso through donations. Thank you. Nous avons besoin de votre aide. S'il vous plaît, vous pouvez soutenir le développement de thasso grâce à des dons. Merci. Wir brauchen Ihre Hilfe. Bitte unterstützen Sie die Entwicklung von thasso durch Spenden. Vielen Dank. Abbiamo bisogno del tuo aiuto. Si prega di sostenere lo sviluppo di thasso attraverso donazioni. Grazie. Nós precisamos da sua ajuda. Por favor, apoie o desenvolvimento de thasso através de doações. Obrigada. Necesitamos tu ayuda. Por favor apoye el desarrollo de thasso con donaciones. Muchas gracias.

thasso: conditions

thasso: newest tweets

Tweets by thasso_info

FDA press releases

FDA Roundup: December 6, 2022 December 6, 2022
FDA Provides Update on External Evaluation to Strengthen Agency’s Human Foods Program December 6, 2022
FDA Approves First Fecal Microbiota Product November 30, 2022
FDA Roundup: November 29, 2022 November 29, 2022
FDA Roundup: November 22, 2022 November 22, 2022

FDA MedWatch

Philips Respironics Recalls Certain BiPAP Machines for Plastic Issue that May Expose Patients to Certain Chemicals of Concern December 6, 2022
Update on Endologix AFX Endovascular AAA Graft Systems and Risk of Type III Endoleak: FDA Safety Communication December 6, 2022
2022 Safety Communications December 6, 2022
Update on Risk of Type III Endoleaks with Use of Endologix AFX Endovascular AAA Graft Systems – FDA Safety Communication December 6, 2022
Certain Philips Respironics BiPAP Machines Recalled Due to a Plastic Issue: FDA Safety Communication December 6, 2022

EMA Press releases

ETF concludes that bivalent original/Omicron BA.4-5 mRNA vaccines may be used for primary vaccination , , 06/12/2022 December 6, 2022
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 28 November - 1 December 2022, PRAC, 02/12/2022 December 2, 2022
EMA recommends withdrawal of pholcodine medicines from EU market, PRAC, 02/12/2022 December 2, 2022
DARWIN EU® welcomes first data partners, , 23/11/2022 November 23, 2022
New Quality Innovation Expert Group (QIG) supports medicine innovation, , 21/11/2022 November 21, 2022

random genetics

Study finds mutations that could contribute to increased liver disease in patient populations December 6, 2022
Alpha-1 antitrypsin deficiency (AATD) is an important and under-recognized genetic cause of liver disease. The most common mutation associated with liver disease results from a single change within the DNA sequence known as the Z mutation—this mutation leads to abnormal processing and significant accumulation of the AAT protein within liver cells, which is the primary […]
A genome-wide association study for overlap of 12 psychiatric disorders December 6, 2022
A team of researchers from Vrije Universiteit Amsterdam in the Netherlands and the Veterans Administration in the U.S. has conducted a genome-wide association study looking into genetic overlap between 12 common psychiatric disorders. The group describes profiling pleiotropic genetic incidences to 12 common psychiatric disorders in their paper published in the journal Nature Genetics.
Scientists discover two master genes critical for hearing December 6, 2022
An international team of scientists led by the LKS Faculty of Medicine, the University of Hong Kong (HKUMed) has uncovered the underlying cause of deafness caused by swelling of the chambers in the inner ear.
Twin study links exercise to beneficial epigenetic changes December 6, 2022
Consistent exercise can change not just waistlines but the very molecules in the human body that influence how genes behave, a new study of twins indicates.
Using spatial single-cell transcriptomics to visualize diffuse midline glioma December 5, 2022
Children diagnosed with diffuse midline gliomas often die within a year after their initial diagnosis since there are no effective treatments yet for this rare cancer. But researchers now have a better understanding of what these tumors look like and can work towards developing new treatment approaches.

Recent Comments

David Walliams on Is genetic testing of value for ALS patients?: “CURED FROM GENITAL HERPES More than 5 years ago I was in pain with this deadly herpes virus, A few…” Nov 7, 16:08
Raul Malkovic on Is genetic testing of value for ALS patients?: “HOW MY WIFE GOT CURED FROM ALS Below is how i got a cure for my wife who suffered from Amyotrophic Lateral Sclerosis…” Nov 6, 21:18
Pamela Erickson on Is genetic testing of value for ALS patients?: “My husband was diagnosed with ALS (amyotrophic lateral sclerosis) when he was 63 years old 4 years ago. The Rilutek…” Aug 13, 13:04
thassodotcom on Unlucky women with BIA-ALCL: An update: “The Therapeutic Goods Agency (TGA) of Australia has just issued a hazard alert concerning the risk of breast implant-associated anaplastic…” Aug 4, 09:17
thassodotcom on Tofacitinib (Xeljanz): Dangers of blood clots in the lungs and of death: “According to its Drug Safety Communication from 07/26/2019, the FDA has approved new warnings about an increased risk of blood…” Aug 4, 08:40

Tag Cloud

Adverse Drug Reaction (ADR) African American Allelic Variant American Food & Drug Administration (FDA) American Food & Drug Administration (FDA) Boxed Warning Breast Cancer Canagliflozin (Invokana) Cancer Children Committee for Medicinal Products for Human Use (CHMP) Companion Test Covid-19 Covid-19 Disease Diabetes Empagliflozin [Jardiance] Epidermal Growth Factor Receptor (EGFR) Erectile Dysfunction Ethnicity European Medicine Agency (EMA) European Medicines Agency (EMA) Food and Drug Administration (FDA) Gene Therapy Genetic Background Genetic Predisposition Genetic Testing Health Canada Non-Small Cell Lung Cancer (NSCLC) Pembrolizumab [Keytruda] Personalized Medicine Phenotype Progressive Multifocal Leukoencephalopathy (PML) Rare Disease Risk Evaluation and Mitigation Strategy (REMS) SARS-CoV-2 Schizophrenia Sodium-Glucose Cotransporter-2 (SGLT2) Stevens Johnson Syndrome [SJS] Targeted Therapy ThassoBase Thasso Post Theragenomic Medicine Toxic Epidermal Necrolysis (TEN) Type 2 Diabetes Vemurafenib [Zelboraf]

thasso

thasso, the new generation glocalized patient network in theragenomic and personalized medicine and individualized drug safety provides access to and sharing of personal and professional information in health and disease to individual patients, to patient subgroups, and to large patient populations worldwide

keys

Social Media, Social Network, Theragenomic Medicine, Social Medicine, Personalized Medicine, Genomic Medicine, Participative Medicine, Targeted Therapy, Individualized Therapy, Personalized Therapy, Individualized Drug Safety, Personalized Drug Safety, Genetic Variants, Allelic Variants, Genotypes, Molecular Phenotypes, Clinical Phenotypes, Companion Test, Heart Disease, Arthritis, Asthma, Diabetes, Hypertension, Malignant Tumors, Breast Cancer, Lung Cancer, Skin Cancer, Erectile Dysfunction, Crowd Sourcing, Patient Sourcing, Participative Sourcing, Collective Experience, Collective Community Wisdom, Apomediary Patient Expert, Patient Cloud,

meta

Register
Log in
Entries feed
Comments feed
WordPress.org

© 2022 thasso | Powered by Responsive Theme

Manage Cookie Consent

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

Functional Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage options Manage services Manage vendors Read more about these purposes

View preferences

{title} {title} {title}